ONCY

Oncolytics Biotech Inc

0.4032

Nov 03 • 11:24 AM ET +0.0032 (0.80%)

Healthcare Biotechnology USA Micro NASD

Peers: GNLX CADL CRDF REPL AGEN CGON ELTX CLDI PDSB RVMD

Index	-
Market Cap	51.41M
Enterprise Value	47.74M
Income	-30.07M
Sales	0.00M
Book/sh	-0.05
Cash/sh	0.03
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Oct 05, 2001

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	12.48
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.35
Current Ratio	1.35
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.27
EPS next Y	-0.20
EPS next Q	-0.05
EPS this Y	-17.90%
EPS next Y	21.72%
EPS next 5Y	4.45%
EPS past 3/5Y	3.00% 6.32%
Sales past 3/5Y	- -
EPS Y/Y TTM	2.05%
Sales Y/Y TTM	-
EPS Q/Q	-35.86%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-46.79% -

Insider Own	1.55%
Insider Trans	0.00%
Inst Own	11.57%
Inst Trans	0.46%
ROA	-277.89%
ROE	-11838.99%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.60%
SMA50	-37.93%
SMA200	-52.97%
Trades

Shs Outstand	124.64M
Shs Float	98.81M
Short Float	9.13%
Short Ratio	8.73
Short Interest	9.03M
52W High	1.30 -68.98%
52W Low	0.39 2.34%
Volatility	7.27% 10.29%
ATR (14)	0.04
RSI (14)	22.76
Beta	1.24
Rel Volume	0.67
Avg Volume	1.03M
Volume	229,308

Perf Week	-12.78%
Perf Month	-32.45%
Perf Quarter	-49.42%
Perf Half Y	-55.93%
Perf YTD	-53.87%
Perf Year	-63.01%
Perf 3Y	-76.56%
Perf 5Y	-81.07%
Perf 10Y	-78.78%
Recom	1.40
Target Price	4.49
Prev Close	0.40
Price	0.40
Change %	0.80%

Consensus

Strong Buy

Avg. Price Target

$4.49

Implied Upside

+1,013.6%

Analysts3incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 13, 2025	Initiated	LLake Street	Buy	$7	+1,636.1%
Oct 06, 2022	Initiated	MMaxim Group	Buy	$3	+644.0%
Feb 17, 2021	Initiated	HH.C. Wainwright	Buy	$15	+3,620.2%

Oct-27-26 09:30AM	Oncolytics Biotech Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers (GlobeNewswire)
Oct-20-26 09:35AM	Oncolytics Biotech to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer (GlobeNewswire)
Oct-14-26 09:30AM	Oncolytics Biotech Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment (GlobeNewswire) +9.84%
04:07AM	Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda (PR Newswire)
Oct-12-26 04:05PM	Oncolytics Biotech Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update (GlobeNewswire) -15.03%
09:30AM	Loading…
Sep-29-26 09:30AM	Oncolytics Biotech Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy (GlobeNewswire)
Sep-28-26 09:30AM	Oncolytics Biotech Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study (GlobeNewswire)
08:00AM	KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 (PR Newswire)
Sep-10-26 08:15AM	Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer (GlobeNewswire)
Aug-18-26 09:00AM	Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer (GlobeNewswire)
Jul-20-26 09:00AM	Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer (GlobeNewswire)
Jul-13-26 10:13AM	Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) (Investors Hub)
09:00AM	Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial (GlobeNewswire)
Jun-16-26 12:42PM	ONCY Stock Surged Today Heres What Securing A Key Immunotherapy Patent Means For Oncolytics (Stocktwits) +11.68%
09:00AM	Oncolytics Biotech Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 (GlobeNewswire)
09:00AM	Loading…
Jun-02-26 09:00AM	Oncolytics Biotech Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer (GlobeNewswire) -12.49%
Jun-01-26 11:26AM	ONCY Stock Heads For Sixth Straight Session Of Gains Lead Therapy Shines in Early Combination Treatment Study (Stocktwits)
09:00AM	Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches (GlobeNewswire)
May-26-26 09:00AM	From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story (ACCESSWIRE)
May-22-26 09:00AM	Oncolytics Biotech to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors (GlobeNewswire)
May-06-26 06:48PM	Oncolytics Biotech Reports Data in Colorectal Cancer Study (IPO-Edge.com)
May-04-26 09:00AM	Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer (GlobeNewswire) +6.61%
Apr-27-26 08:10AM	Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study (GlobeNewswire) -5.95%
Apr-06-26 09:00AM	Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer (GlobeNewswire)
Apr-01-26 09:00AM	Oncolytics Biotech Completes Domicile Change to the United States (GlobeNewswire) +9.58%
Mar-19-26 09:00AM	Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 (GlobeNewswire)
Mar-05-26 09:00AM	Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types (PR Newswire)
Mar-03-26 09:00AM	Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion (PR Newswire)
Mar-02-26 09:00AM	Oncolytics Biotech Launches Randomized Colorectal Cancer Study (GlobeNewswire) -9.73%
Feb-25-26 09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire)
10:58AM	Loading…
Feb-24-26 10:58AM	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge (PR Newswire) +6.60%
09:00AM	Oncolytics Biotech to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer (GlobeNewswire)
Feb-17-26 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire) -7.79%
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire) -7.04%
08:55AM	Oncolytics receives FDA Fast Track Designation for pelareorep (TipRanks)
Feb-04-26 08:50AM	Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer (GlobeNewswire)
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-15-26 04:01PM	Oncolytics Biotech Announces Results of Special Meeting of Shareholders (GlobeNewswire) -7.33%
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire)
09:00AM	Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics (GlobeNewswire)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
09:00AM	Oncolytics Biotech Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer (GlobeNewswire)
04:23AM	Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances (Insider Monkey)
Jan-10-26 09:05AM	Oncolytics outlines strategic rationale for proposal to change jurisdiction (TipRanks)
Jan-09-26 09:00AM	Oncolytics Biotech Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada (GlobeNewswire)
Jan-08-26 09:00AM	Oncolytics Biotech Provides Update on Intellectual Property Strategy and Patent Filings (Business Wire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
09:00AM	Oncolytics Biotech Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen OReilly, Dr. Neil Segal, and Dr. Van Morris (Business Wire)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire) +12.68%
09:00AM	Oncolytics Biotech Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer (Business Wire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-09-25 06:00PM	Oncolytics Biotech Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada (Business Wire)
Dec-03-25 09:35AM	Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-20-25 04:05PM	Oncolytics Biotech Provides Update on Special Meeting of Shareholders (Business Wire)
Nov-19-25 12:00PM	All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy (Zacks)
09:00AM	Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer (Business Wire)
Nov-04-25 08:00AM	Oncolytics Biotech Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy (Business Wire) -11.48%
Oct-28-25 07:30AM	Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care (PR Newswire)
Oct-20-25 09:00AM	Oncolytics Biotech Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada (PR Newswire)
Sep-29-25 08:30AM	Oncolytics Biotech Announces Update for Potential First-Line Pancreatic Cancer Registration Study (PR Newswire) +9.30%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
07:00AM	Oncolytics Biotech Provides Update on GOBLET Study Progress and U.S. Site Expansion (PR Newswire)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) +20.75%
07:00AM	Oncolytics Biotech Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions (PR Newswire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire) +10.58%
09:10AM	Oncolytics Biotech Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors (PR Newswire)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
08:30AM	Oncolytics Biotech Announces Upcoming Investor Conferences in September (PR Newswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire) -7.81%
12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-11-25 04:55PM	Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
Aug-08-25 09:05AM	Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep (PR Newswire) -6.20%
09:00AM	Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock Exchange (PR Newswire)
Aug-05-25 08:30AM	Oncolytics Biotech Announces Upcoming Annual General Meeting and Second Quarter Financial Results (PR Newswire) +7.58%
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.42%
08:30AM	Oncolytics Biotech to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End (PR Newswire)
Jul-23-25 09:39AM	Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire)
09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-22-25 03:32PM	Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules (PR Newswire)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +10.62% +5.60%
08:30AM	Oncolytics Biotech Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) -7.08%
08:30AM	Oncolytics Biotech to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers (PR Newswire)
Jul-08-25 08:30AM	Oncolytics Biotech Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies (PR Newswire) +23.76%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
07:00AM	Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) +5.79%
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -6.74%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +10.76%
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 07:00AM	Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs (PR Newswire) +34.10%
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
07:00AM	Oncolytics Biotech to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parsons James T.	Director	Mar 11 '26	Buy	1.03	10,000	10,300	41,849	Mar 13 08:00 AM
Kelly Jared	Chief Executive Officer	Mar 12 '26	Buy	0.96	5,050	4,848	114,050	Mar 13 08:00 AM
Kelly Jared	Chief Executive Officer	Feb 12 '26	Buy	0.84	29,500	24,839	109,000	Feb 13 07:00 AM
Kelly Jared	Chief Executive Officer	Feb 11 '26	Buy	0.84	5,600	4,682	79,500	Feb 13 07:00 AM
Look Kirk	Chief Financial Officer	Feb 12 '26	Buy	0.84	12,000	10,104	287,515	Feb 13 07:00 AM
Pisano Wayne	Director	Feb 12 '26	Buy	0.84	30,000	25,338	492,414	Feb 13 07:00 AM
Heineman Thomas Charles	Chief Medical Officer	Feb 12 '26	Buy	0.83	12,132	10,033	282,818	Feb 13 07:00 AM
Brown Deborah Margaret	Director	Feb 12 '26	Buy	0.85	25,000	21,240	109,851	Feb 13 07:00 AM
Hagerman Allison	VP, Product Development	Feb 12 '26	Buy	0.83	10,000	8,298	115,059	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 11 '26	Buy	0.83	60,000	49,590	526,991	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 12 '26	Buy	0.85	40,000	33,864	566,991	Feb 13 07:00 AM
Aromando Andrew	Chief Business Officer	Feb 11 '26	Buy	0.86	29,600	25,418	55,100	Feb 13 07:00 AM
Andrews Patricia S	Director	Feb 12 '26	Buy	0.86	35,400	30,292	78,128	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Jan 16 '26	Buy	1.04	100,000	103,770	466,991	Jan 20 04:30 PM

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

L.L.M.Mr. Jared Kelly J.D.

Ph.D.Dr. Thomas C. Heineman M.D.

Chief Operating OfficerMr. John McAdory

P.M.P.Ms. Allison Hagerman P.Eng.

Director of Investor Relations & CommunicationJon Patton

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCY

Oncolytics Biotech Inc

Upgrade your Finviz experience